A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Inclusion Criteria:

Master Inclusion Criteria applicable to all substudies:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Contraception use during treatment and at least 90 days after final dose.

• Confirmed CD19 expression if prior anti-CD19 therapy.

Substudy 1 Specific Inclusion Criteria:

• Participants with CLL must require treatment according to the international workshopon Chronic Lymphocytic Leukemia (iwCLL) criteria.

• SLL: at least 1 measurable site per Lugano.

• Absolute lymphocyte count (ALC) <25000 cells/mcL.

• Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL.

• Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor (BTKi)-sensitive.

Substudy 2 Specific Inclusion Criteria:

• MCL diagnosis per WHO.

• Clinical Stage II, III, or IV by Ann Arbor Classification.

• At least 1 measurable site per Lugano.

• ALC < 25000 cells/mcL.

• Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy includingBTKi.

Substudy 3 Specific Inclusion Criteria:

• At least 1 measurable site as per Lugano.

• Left ventricular ejection fraction (LVEF) ≥50%.

• Participant must be no older than 79 years of age at the time of signing ICF.

• Contraception at least 90 days after last dose of surovatamig or 4 months after lastdose of vincristine, and 6 months after the last dose of cyclophosphamide, ordoxorubicin.

• Cohort 3A:

1. Histologically confirmed diagnosis of previously untreated large B-cellLymphoma (LBCL) per WHO 2022.

2. R/R B-NHL after at least 1 prior lines of systemic therapy.

3. International Prognostic Index (IPI) 2-5.

• Cohort 3B:

1. Histologically confirmed diagnosis of previously untreated large B-cellLymphoma (LBCL) per WHO 2022.

2. IPI score of 2 to 5.

Exclusion Criteria:

Master Exclusion Criteria applicable to all substudies:

• Central nervous system (CNS) lymphoma.

• Surgery within 14 days of study drug.

• Clinically significant cardiovascular (CV) disease.

• Unresolved Grade >2 AEs from prior anticancer therapy (except alopecia or fatigue).

• Any systemic therapy within 5 half-lives or 21 days (whichever is shorter) prior totreatment.

• Radiation therapy within 28 days.

• Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT)within 12 weeks or prior T-cell engager (TCE) within 8 weeks.

• Prior Grade > 3 cytokine release syndrome (CRS) or immune effector cell-associatedneurotoxicity syndrome (ICANS) event.

• Prior allogeneic HSCT or solid organ transplantation within 24 weeks of startingCycle 1 Day 1.

• Active, significant, uncontrolled infection or autoimmune disease requiring systemictherapy including participants with known history of haemophagocyticlymphohistiocytosis (HLH).

Substudy 1 Specific Exclusion Criteria:

• CLL/SLL transformation to more aggressive form of lymphoma.

• Cohort 1B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or strokewithin 24 weeks, GI malabsorption, receiving vitamin K antagonist.

Substudy 3 Specific Exclusion Criteria:

• Mediastinal grey-zone lymphoma, Burkitt, Richter's transformation, primary effusionlarge B-cell lymphoma (LBCL).

• Cumulative dose of anthracycline >150 mg/m2.